Chronic Lymphocytic Leukemia (CLL)
Clinical Trials
Updated: February 2011
Leukemia/BMT Program of BC
For trials updates from the L/BMT Program, please refer to the Clinical Trials page on this website.
BC Cancer Agency
Currently, there is one CLL trial at BCCA open to enrollment.
Trial Name:
LYCL3: A Genetic Risk Stratified, Randomized Phase II Study of Four Fludarabine/Antibody Combinations For Patients with Symptomatic, Previously Untreated, Chronic Lymphocytic Leukemia
Principal Investigator:
Dr. Cynthia Toze
Nurse Coordinator:
Ms. Debbie Jepson
t. 604.877.6000 ext. 3567
| The information contained in these guidelines is a statement of consensus of Leukemia/BMT Program of BC professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. Use of these guidelines and documents is at your own risk and is subject to the Leukemia/BMT Program of BC’s terms of use available at Terms of Use. |